Clinical Trial Update: Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers [Phase 4]

View source ↗

Summary

Phase 4 update on the use of INTEGRA Flowable Wound Matrix for diabetic foot ulcers. The trial was terminated and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Foot Ulcer

Drugs mentioned

• INTEGRA Flowable Wound Matrix

Snippet

Sponsor: Georgetown University | Conditions: Diabetes, Foot Ulcer | Phase 4 | Status: TERMINATED | Results posted: 2014-03-17